#Clinical Trials #Vienna #Austria #RNA Sequencing #Lexogen

Lexogen's New GCLP-Compliant NGS Services

In a significant move to bolster its next-generation sequencing (NGS) capabilities, Lexogen has announced a new lineup of services that are compliant with the World Health Organization's Good Clinical Laboratory Practice (GCLP) guidelines. This expansion is particularly aimed at supporting clinical research and clinical trials, where stringent controls on sample traceability, documentation, and data integrity are paramount.

Lexogen, a noted player in RNA sequencing technologies, has tailored its offerings to meet the specialized needs of healthcare professionals and researchers engaged in trials that demand meticulous oversight. The GCLP-compliant workflows cover every step of the research process, from project planning to data delivery, thereby providing a structured framework that ensures high standards of quality throughout the entire sequencing process.

One of the hallmarks of Lexogen's new service is the integration of its proprietary RNA sequencing and library preparation products. Manufactured in accordance with ISO 13485 standards, these products are designed to maintain rigorous quality assurance, providing enhanced traceability and process documentation. To further enhance the service, Lexogen allows the use of other commercially available products and reagents, contingent upon proper evaluation and qualification to adhere to the specific requirements of individual projects.

Stephane Barges, CEO of Lexogen, emphasized the importance of such partnerships in the realm of clinical research. He stated, "Clinical research teams need sequencing partners that can deliver robust data through laboratory activities that are controlled, traceable, auditable, and reconstructable." This sentiment echoes the raised expectations within the industry, as researchers increasingly seek collaborators who can deliver not just raw data, but comprehensive support with a focus on quality and precision.

Prior to the commencement of any project, Lexogen works closely with clients to define the exact parameters, including sample types and analytical objectives. These discussions culminate in the creation of a detailed study plan that outlines expectations and deliverables, ensuring that all parties are aligned from the outset.

Importantly, while Lexogen adheres to its defined GCLP controls, it's crucial to note that these compliance measures are based on their internal assessments, and not dependent on external certification or accreditation. This self-regulated integrity allows Lexogen to implement necessary controls without the lengthy timeline often associated with external verification processes.

As the landscape of clinical research continues to evolve, Lexogen remains dedicated to pushing the boundaries of what's possible within RNA sequencing. By introducing GCLP-compliant services, they are not only enhancing their product offerings but also reinforcing their commitment to advancing the quality and reliability of data that drives the next generation of medical discoveries.

Conclusion

With the launch of these GCLP-compliant workflows, Lexogen is poised to serve a pivotal role in the clinical research arena, where the demand for reliable, high-integrity sequencing data is more crucial than ever. For researchers looking for robust, traceable data gathering processes, Lexogen offers a blend of innovation and quality assurance that stands out in the biotechnology landscape.

For more detailed information on their services, visit Lexogen's official website or reach out directly via email.